Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
KATHRYN GOLD
🇺🇸
United States
Country
🇺🇸
United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1
Active, not recruiting
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Drug: Avelumab
Drug: Palbociclib
Drug: Cetuximab
Subscribe
First Posted Date
2018-04-13
Last Posted Date
2024-11-12
Lead Sponsor
Kathryn Gold
Target Recruit Count
24
Registration Number
NCT03498378
Locations
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy